Acexamic Acid

Summary

Acexamic Acid (CHEMBL2105922) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 173.21 Da · C8H15NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105922
Name	Acexamic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2005
Molecular formula	C8H15NO3
Molecular weight	173.21
InChIKey	WDSCBUNMANHPFH-UHFFFAOYSA-N

SMILES: CC(=O)NCCCCCC(=O)O

IUPAC name: 6-acetamidohexanoic acid

Also known as: .epsilon.-acetamidocaproic acid, Acexamic acid, Acide acexamique, Acido acexamico, CY 153, CY-153, NSC-12945, ACEXAMIC ACID, SID170466424, SID144204930, ACEXAMIC-ACID, acexamic-acid

Parent form; salt/anhydrous children: CHEMBL6068530

Patent coverage: 1,159 distinct patent families (3,741 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Alpha-1A adrenergic receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).